Psoriasis is an immune-mediated chronic, systemic, and inflammatory disease, with its core pathogenesis pathway regulated by the Janus kinase (JAK) family mediated JAK-STAT pathway.

1、 Drug name

1. Common name: Deucravatinib;

2. Product Name: SOTYKTU ™。

2、 Indications

Deuterium can be used to treat moderate to severe plaque psoriasis in adults, and is suitable for patients receiving systemic therapy or phototherapy.

3、 Specifications and characteristics

1. Specification: 6mg

2. Appearance: Tablets

4、 Main components

Active ingredient: Deuterium Celecoxib

5、 Usage and dosage

1. Recommended dosage: 6mg orally, once daily, before or after meals.

2. Medication method: Swallow the whole tablet, do not crush, cut or chew.

3. Omission treatment: If remembered on the same day, take the medication as scheduled the next day.

4. Vomiting treatment: Vomiting after taking medication does not require supplementation.

6、 Dose adjustment

1. Liver dysfunction: contraindicated for patients with severe liver injury (Child Pugh C grade); Mild to moderate liver injury does not require dose adjustment.

2. Infection or laboratory abnormalities: If severe infection occurs, liver enzymes increase by ≥ 3 times ULN, or creatine kinase (CPK) significantly increases, medication should be suspended or discontinued.

7、 Medication precautions

1. Infection risk: tuberculosis (TB) and hepatitis B/C should be screened before treatment to avoid being used in patients with active infection.

2. Vaccination: Avoid using live vaccines and complete recommended immunization before treatment.

3. Monitoring requirements: Regularly check liver function, blood lipids (especially triglycerides), and blood routine.

4. Muscle symptoms: If there is unexplained muscle pain or weakness accompanied by fever, seek medical attention immediately.

8、 Medication for special populations

1. Pregnant women: Prohibited, animal tests show no teratogenicity at high doses, but human data is insufficient.

2. Breastfeeding period: Suspend medication or stop breastfeeding.

3. Elderly patients: Patients aged 65 and above have an increased risk of serious adverse reactions (such as infections).

4. Liver and kidney dysfunction: prohibited for severe liver injury; Renal function is impaired and dosage adjustment is necessary.

9、 Adverse reactions

1. Common (≥ 1%): Upper respiratory tract infection (19.2%), elevated CPK (2.7%), oral herpes (2.0%), oral ulcers (1.9%), folliculitis (1.7%), acne (1.4%).

2. Serious reactions: infection (pneumonia, COVID-19), malignant tumor (lymphoma), hepatotoxicity, rhabdomyolysis.

10、 Contraindications

It is contraindicated for individuals allergic to deuteroxenib or any excipients.

11、 Drug interactions

1. Strong CYP3A4 inducers/inhibitors: Avoid combination therapy (such as rifampicin and ketoconazole).

2. Live vaccines: The interval between vaccinations should be cautious.

12、 Storage method

1. Storage temperature: 20-25 ° C (short-term 15-30 ° C allowed).

2. Keep the original packaging and avoid moisture and light exposure.

Deucravacitinibinformation